BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hairy Cell Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01711632
- Collaborators
- National Cancer Institute (NCI)
- Northwestern University
- Ohio State University
- Dana-Farber Cancer Institute
- Scripps Clinic
- Northwell Health
- Investigators
- Principal Investigator: Jae H. Park, MD Memorial Sloan Kettering Cancer Center